ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2026

Mar 4, 2026

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ALGORAE PHARMACEUTICALS LIMITED

ABN 14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DAVID HAINSWORTH
Date of last notice	22 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgivingrise to the relevant interest.	UNION SQUARE CAPITAL PTY LTD<ENDEAVOR A/C>Director & Controlling Shareholder
Date of change	5 March 2026
No. of securities held prior to change	Indirect5,625,000 Ordinary Shares312,500 1AIO options1,125,000 Unlisted options exercisable at $0.014exp 1/12/2029Direct20,000,000 Ordinary Shares20,000,000 Performance Rights (AGM 2024)30,000,000 Performance Rights (AGM 2025)4,000,000 Unlisted options exercisable at$0.014 exp 1/12/2029
Class	a.Ordinary Sharesb.1AIO options
Number acquired	a.312,500
Number disposed	b.312,500
Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation	$3,750

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of s	No. of s
	No. of s	ecuriti	es held	after	chang	e		Indire	ct
								5,937112	,500 Ord000 Uli	inary Std	haresti	ib	l t $0	014
								,exp 1Direc200	, n/12/2029t0000 O	se op i	ons exh	rcsa	e a .
								,20,00	, r0,000 Pe	naryrforman	aresce Righ	ts (AG	M 2024)
								30,004,000	0,000 Pe,000 Unli	rformansted op	ce Rightions ex	ts (AGercisab	M 2025)le at $0.	014
								exp 1	/12/2029
	Nature	of chan	ge					Exerc	ise of op	tions.
ExamplexerciseunderparticipaPart 2 – C	Examplexerciseunderparticipa	e: on-mof odividtion in	arket tptions,end buy-b	rade, oissuereinveack	ff-markof sstment	et tradeecurities plan	, ,
		hange	of dir	ector’s	intere	sts in c	ontracts

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related	N/A
prior to change
Note: Details are only required for a contract in relation to
which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts	No.
detailed above traded during a+closed period where
prior written clearance was required?
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?
If prior written clearance was provided, on what date	N/A
was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011